Percutaneous cryoablation could potentially be used as a last line of defense to halt individual spots of remaining metastatic breast cancer by freezing and destroying tumours, according to study presented at the Society of Interventional Radiology’s 37th Annual Scientific Meeting in San Francisco, USA.
A new study presented at the Society of Interventional Radiology’s 37th Annual Scientific Meeting in San Francisco, USA, shows that a lower-dosage CT-guided lung biopsy protocol results in 66% average dose reduction with no difference in nodule size, or biopsy difficulty.
Delcath Systems has announced that Quintiles will provide a specialised team of medical science liaisons to support the launch of the hepatic Chemosat delivery system for the treatment of cancers in the liver in France, Germany, Italy, Netherlands, Spain, Ireland and the United Kingdom. In addition, it will provide medical communication to support patient advocacy, key opinion leader development, and field force materials.
Avinger has announced the enrolment of the first US patient in the multicentre, non-randomised CONNECT II global clinical trial designed to evaluate the safety and efficacy of the company’s Ocelot, the first-ever chronic total occlusion crossing catheter to use real-time intravascular optical coherence tomography (OCT) imaging technology.
Covidien has announced the launch of the HALO60 ablation catheter, the latest addition to the HALO family of catheters for the endoscopic treatment of Barrett’s esophagus.
Boston Scientific Corporation (NYSE: BSX) announces the U.S. and international launch of the WallFlex® Biliary Transhepatic Stent System. This third-generation stent platform is now available with a percutaneous delivery system designed for use by interventional radiologists in the palliative treatment of biliary strictures produced by malignant tumors. The WallFlex Biliary Transhepatic Fully Covered Stent System is also available for the treatment of benign biliary strictures in CE marked countries.
Delcath Systems announced on 27 February that the first patients in Germany have been treated with the Delcath Hepatic Chemosat Delivery System at the Johann Wolfgang Goethe University Hospital, a premier European cancer treatment and research center located in Frankfurt. The cases were treated as part of the initial launch and training agreement the company announced with the hospital in December 2011.
SARAH (Sorafenib versus radioembolization in advanced hepatocellular carcinoma) is designed to directly compare the effectiveness of radioembolization with yttrium-90 resin microspheres (Sirtex) versus sorafenib (Bayer HealthCare Pharmaceuticals), a systemic therapy that is the current standard of care for patients with non-operable advanced hepatocellular carcinoma (HCC).
ReCor Medical has announced that its Paradise percutaneous renal denervation system ultrasound platform for achieving renal denervation has received CE mark. Paradise is designed to treat patients with ‘resistant’ hypertension.
On 15 February, Delcath Systems and the European Institute of Oncology (Instituto Europeo di Oncologia – IEO) introduced the Delcath Hepatic Chemosat Delivery System to media at a press conference and discussed the status of the first European patients treated with the technology.
On 13 February, Medtronic launched two clinical studies to evaluate the use of its Symplicity renal denervation system for treatment-resistant hypertension across different conditions in a real-world setting.
Hansen Medical announced it will showcase its Magellan robotic system at the Leipzig Interventional Course (LINC), from 25–28 January 2012 at the Trade Fair Leipzig, Hall 4, in Leipzig, Germany.
Robert J Kennedy, interventional radiologist, Holmes Regional Medical Center, Melbourne, Florida, USA, presented data on thrombus resolution and haemodynamic recovery using ultrasound accelerated thrombolysis in acute pulmonary embolism at the International Symposium on Endovascular Therapy (ISET) in Miami, Florida.
A minimally invasive embolization procedure, in which polyvinyl alcohol (PVA) particles are injected into the blood vessels to the nose, may be an effective therapy to decrease or stop nosebleed recurrence rates, according to a study being presented at the 24th annual International Symposium on Endovascular Therapy (ISET), Miami, USA.
At CIRSE 2011, in Munich, Germany, two experts told delegates what the evidence on renal denervation says so far, what studies ought to examine in the future, and what the potential downsides of the catheter-based treatment could be.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos